Current status of gene therapy for breast cancer: progress and challenges

Cian M McCrudden, Helen O McCarthy

Research output: Contribution to journalReview article

12 Citations (Scopus)
321 Downloads (Pure)

Abstract

Breast cancer is characterized by a series of genetic mutations and is therefore ideally placed for gene therapy intervention. The aim of gene therapy is to deliver a nucleic acid-based drug to either correct or destroy the cells harboring the genetic aberration. More recently, cancer gene therapy has evolved to also encompass delivery of RNA interference technologies, as well as cancer DNA vaccines. However, the bottleneck in creating such nucleic acid pharmaceuticals lies in the delivery. Deliverability of DNA is limited as it is prone to circulating nucleases; therefore, numerous strategies have been employed to aid with biological transport. This review will discuss some of the viral and nonviral approaches to breast cancer gene therapy, and present the findings of clinical trials of these therapies in breast cancer patients. Also detailed are some of the most recent developments in nonviral approaches to targeting in breast cancer gene therapy, including transcriptional control, and the development of recombinant, multifunctional bio-inspired systems. Lastly, DNA vaccines for breast cancer are documented, with comment on requirements for successful pharmaceutical product development.

Original languageEnglish
Pages (from-to)209-20
Number of pages12
JournalThe application of clinical genetics
Volume7
DOIs
Publication statusPublished - 10 Nov 2014

Fingerprint

Genetic Therapy
Breast Neoplasms
Neoplasm Genes
DNA Vaccines
Nucleic Acids
Biological Transport
Pharmaceutical Preparations
Cancer Vaccines
RNA Interference
Clinical Trials
Technology
Mutation
DNA
Therapeutics

Cite this

@article{7d5d742527ce47fbb8ee5c2389a552d0,
title = "Current status of gene therapy for breast cancer: progress and challenges",
abstract = "Breast cancer is characterized by a series of genetic mutations and is therefore ideally placed for gene therapy intervention. The aim of gene therapy is to deliver a nucleic acid-based drug to either correct or destroy the cells harboring the genetic aberration. More recently, cancer gene therapy has evolved to also encompass delivery of RNA interference technologies, as well as cancer DNA vaccines. However, the bottleneck in creating such nucleic acid pharmaceuticals lies in the delivery. Deliverability of DNA is limited as it is prone to circulating nucleases; therefore, numerous strategies have been employed to aid with biological transport. This review will discuss some of the viral and nonviral approaches to breast cancer gene therapy, and present the findings of clinical trials of these therapies in breast cancer patients. Also detailed are some of the most recent developments in nonviral approaches to targeting in breast cancer gene therapy, including transcriptional control, and the development of recombinant, multifunctional bio-inspired systems. Lastly, DNA vaccines for breast cancer are documented, with comment on requirements for successful pharmaceutical product development.",
author = "McCrudden, {Cian M} and McCarthy, {Helen O}",
year = "2014",
month = "11",
day = "10",
doi = "10.2147/TACG.S54992",
language = "English",
volume = "7",
pages = "209--20",
journal = "The application of clinical genetics",
issn = "1178-704X",
publisher = "Dove Medical Press Ltd.",

}

Current status of gene therapy for breast cancer: progress and challenges. / McCrudden, Cian M; McCarthy, Helen O.

In: The application of clinical genetics, Vol. 7, 10.11.2014, p. 209-20.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current status of gene therapy for breast cancer: progress and challenges

AU - McCrudden, Cian M

AU - McCarthy, Helen O

PY - 2014/11/10

Y1 - 2014/11/10

N2 - Breast cancer is characterized by a series of genetic mutations and is therefore ideally placed for gene therapy intervention. The aim of gene therapy is to deliver a nucleic acid-based drug to either correct or destroy the cells harboring the genetic aberration. More recently, cancer gene therapy has evolved to also encompass delivery of RNA interference technologies, as well as cancer DNA vaccines. However, the bottleneck in creating such nucleic acid pharmaceuticals lies in the delivery. Deliverability of DNA is limited as it is prone to circulating nucleases; therefore, numerous strategies have been employed to aid with biological transport. This review will discuss some of the viral and nonviral approaches to breast cancer gene therapy, and present the findings of clinical trials of these therapies in breast cancer patients. Also detailed are some of the most recent developments in nonviral approaches to targeting in breast cancer gene therapy, including transcriptional control, and the development of recombinant, multifunctional bio-inspired systems. Lastly, DNA vaccines for breast cancer are documented, with comment on requirements for successful pharmaceutical product development.

AB - Breast cancer is characterized by a series of genetic mutations and is therefore ideally placed for gene therapy intervention. The aim of gene therapy is to deliver a nucleic acid-based drug to either correct or destroy the cells harboring the genetic aberration. More recently, cancer gene therapy has evolved to also encompass delivery of RNA interference technologies, as well as cancer DNA vaccines. However, the bottleneck in creating such nucleic acid pharmaceuticals lies in the delivery. Deliverability of DNA is limited as it is prone to circulating nucleases; therefore, numerous strategies have been employed to aid with biological transport. This review will discuss some of the viral and nonviral approaches to breast cancer gene therapy, and present the findings of clinical trials of these therapies in breast cancer patients. Also detailed are some of the most recent developments in nonviral approaches to targeting in breast cancer gene therapy, including transcriptional control, and the development of recombinant, multifunctional bio-inspired systems. Lastly, DNA vaccines for breast cancer are documented, with comment on requirements for successful pharmaceutical product development.

U2 - 10.2147/TACG.S54992

DO - 10.2147/TACG.S54992

M3 - Review article

C2 - 25419154

VL - 7

SP - 209

EP - 220

JO - The application of clinical genetics

JF - The application of clinical genetics

SN - 1178-704X

ER -